21.3.2004
No items found.

Medicines

Commission Regulation (EC) No. 1084/2003 of 3 June 2003 concerning the examination of variations to the terms of a marketing authorisation for medicinal products for human use and veterinary medicinal products granted by a competent authority of a Member State; Commission Regulation (EC) No. 1085/2003 of 3 June 2003 concerning the examination of variations to the terms of a marketing authorisation for medicinal products for human use and veterinary medicinal products falling within the scope of Council Regulation (EEC) No. 2309/93 Official Journal EU L 159, 27 June 2003

Hitherto, EU law has in effect made provision for two different procedures when registering medicinal products (i) registration with the competent authority in the member state (for instance, following the accession of CR to the EU, by the Medicinal Products State Inspection Office in the CR) and (ii) registration via a centralised evaluation body (European Medicines Evaluation Agency, London).

The two new regulations set out the steps for variations in marketing authorisations applicable under both procedures. The intention is to simplify and expedite procedures for certain types of variations in registration, as well as to clarify legislation in this area. Upon registration in a member state, the variation will be examined by a competent authority of the member state. Provisions governing administrative procedures and requirements for variation of registration will differ according to the type of variation, as set out in the attached schedules. Procedures have been simplified, particularly where there is a need to adopt emergency measures or to combat an influenza pandemic.

Commission Directive 2003/94/EC of 8 October 2003 setting out the principles and guidelines for good manufacturing practice relating to medicinal products for human use

Official Journal of the EU L 262 of 14 October 2003

This Directive introduced a change in the requirements relating to correct manufacture of medicinal products intended for human use and replaces existing Directive 91/356/EEC. It incorporates new provisions on the rights of supervisory bodies to carry out inspections, quality control and other matters requiring attention following experience in implementing the existing provisions. At national level the Directive is mostly reflected in secondary legislation. The deadline for implementation of the Directive into national legal order expires on 30 April 2004.

Other articles

8.8.2025
News

Project Financing of a Strategic Logistics Complex in Nymburk

KŠB provided legal advice to Facility Develop Group in securing two separate financings granted by Trinity Bank. The funds will be used for the development and expansion of a large logistics park in Nymburk, which is of key importance to the infrastructure of the entire Central Bohemian Region.
5.8.2025
News

Legal Advisory to Japanese Group Ushio on the Acquisition of a Division of ams-OSRAM

The KŠB team, led by partner Dagmar Dubecká and attorney Jana Guričová, provided legal advisory to Japanese company Ushio Inc., a global leader in semiconductor technologies and specialized lighting for the automotive and industrial sectors, in connection with its acquisition of the Entertainment& Industrial Lamps segment from the Austrian-based ams-OSRAM Group, a company with over a century of history.
28.7.2025
News

Smetanova Litomyšl Comes to a Close with Music and a Message of Solidarity

This year’s edition of the Smetanova Litomyšl festival concluded with the concert Grand Finale – An American Story, held under the patronage of our firm. In addition to delivering a remarkable musical experience, the evening also served a charitable purpose: proceeds supported the Olga Havel Foundation (Výbor dobré vůle – Nadace Olgy Havlové), helping young people from disadvantaged backgrounds pursue their education.